Site-specific labeling of proteins is often a prerequisite for biophysical and biochemical characterization. Chemical modification of a unique cysteine residue is among the most facile methods for site-specific labeling of proteins. However, many proteins have multiple reactive cysteines, which must be mutated to other residues to enable labeling of unique positions. This trial-and-error process often results in cysteine-free proteins with reduced activity or stability.
Introduction
Modification of a unique cysteine residue with a maleimide or iodoacetamide conjugated probe is a widely used method of producing site-specifically labeled proteins. These two chemistries have a long history in the literature starting from the first description of the reaction between iodoacetamide and thiols in 1933 1, 2 . The value of this reaction to protein biochemistry was reified shortly thereafter in the first published reports of iodoacetamide's reaction with purified, native proteins 3, 4 . The promise of maleimide chemistry was confirmed in 1949 when the reaction between substituted maleimides and thiols was shown to proceed at room temperature in water on the minute timescale with a nearly stoichiometric yield 5 . Shortly thereafter, the reaction of N-ethylmaleimide with actin was reported constituting the first published study to demonstrate that substituted maleimides react specifically with purified proteins 6 . In the following decade, creative applications of maleimide chemistry began appearing. The first deployment of bis-maleimides as a crosslinking agent was published in 1956 7 . Four years later, the first chromophore conjugated maleimide was used as an indicator for cysteine residues in proteolysis fragments of serum albumin 8 . Because of their high reaction yields under mild conditions, early biochemists appreciated the potential of substituted iodacetamides and maleimides to label proteins natively.
Today, cysteine directed probes are ubiquitous in protein science. Common substituents include crosslinkers, fluorophores, affinity tags such as biotin or digoxigenin, nitroxide spin labels, and silanes for surface immobilization. Such thiol-reactive probes are used in a range of applications including bulk kinetic measurements, single molecule biophysics, surface plasmon resonance, nuclear magnetic resonance and electron spin resonance spectroscopy 9 . A growing number of thiol-reactive probes are commercially available. As of writing, a search of Thermo Fisher's online catalog alone contains over 90 thiol-reactive labeling kits and at least 13 thiol-reactive crosslinkers. Site-specific labeling has benefited the study of many protein families. However, in order to label thiols, one must first generate single cysteine mutants of a protein of interest.
Typically, cysteines are replaced by serines or alanines, in an empirical trial-and-error process that often yields modified cysteine-less mutants that have reduced activity or stability ( Figure   1A ). Hence, a rational method to produce active cysteine-less protein variants would be quite desirable to contemporary protein science.
Along these lines, we sought to generate a cysteine-less variant of a well studied group II chaperonin, MmCpn. Chaperonins are ATP-driven components of the cellular protein folding machinery and are essential in all free-living organisms. They comprise two structurally related chaperonin families generally called group I and group II chaperonins. Group I chaperonins are present in prokaryotes and the endosymbiotic organelles, chloroplasts and mitochondria 10 .
Group I chaperonins are also, albeit comparatively rarely, found in archaeal genomes. The study of the archetypal group I chaperonin, GroEL from Escherichia coli, has long benefitted from the availability of a cysteine-less variant 11 that enabled many mechanistic studies. Even for this successful example, the cysteine-less GroEL variants exhibit impaired activity compared to wild type 11 . Comparable studies have not been possible thus far in the group II chaperonins.
The group II chaperonins are found exclusively in the archaeal and eukaryotic cytosol 12 .
Broadly, they are a family of ATP-driven hexadecameric chaperones with two stacked, eight membered rings per complex. These rings are related by a two-fold symmetry axis, which lies along the equator of the complex ( Figure 1B , dashed line). Orthogonal to the two-fold axis is the eight-fold axis, which defines the intra-ring symmetry of the complex. The eukaryotic group II chaperonin, termed TRiC or CCT comprises eight parologous subunits of which four bind ATP.
By contrast, the archaeal group IIs are prototypically α8β8 complexes. Other configurations have been reported including group IIs with 9-fold symmetry 13, 14 . Here we will discuss the homohexadecameric group II chaperonin from Methanococcus maripaludis, MmCpn, which has proven itself to be a very useful model group II chaperonin. Previous efforts demonstrated that a cysteine-less mutant of MmCpn could be produced from a combination of serine, alanine and threonine point mutations 15, 16 . This MmCpn mutant, termed ∆Cys (MmCpnΔCys), assembles correctly and can bind unfolded proteins. It can also close its lid upon the addition of ADP-AlFx, which acts as a transition state analog for the ATP hydrolysis reaction. However, MmCpn∆Cys is very poorly expressed in E. coli, and thus unsuitable for applications requiring milligram quantities of protein. To engineer a stable and highly expressed cysteine-less MmCpn variant for structural and biophysical work, we sought an alternative strategy to identify position-specific cysteine substitutions. We developed a rational approach using natural variation among extant ortholog sequences, which yielded a well expressed chaperonin with wild-type client folding activity. This effort provides proof-of-concept for our strategy to engineer amino acid replacements in proteins.
Results

A rational strategy to design a cysteine-less chaperonin variant
In order to design a functional, well-expressed cysteine-less chaperonin mutant we sought to integrate available structural information about MmCpn with phylogeny, using extant sequence information for homologous archaeal chaperonins. We reasoned that amino acid substitutions derived from close MmCpn homologs would be well tolerated by this chaperonin. To this end we amassed 2981 group II chaperonin sequences from the NCBI non-redundant protein sequence database using BLAST 17 . Each of these extant chaperonin sequences was aligned to the WT MmCpn sequence using the program Water from the EMBOSS Suite 18 . Water implements the Smith-Waterman sequence alignment algorithm which guarantees optimal pairwise local sequence alignment given an affine gap penalty 19 . To better interpret the information from the alignments, the sequences in the database were then rank ordered by their percentage identity with MmCpn.
The overall strategy of our approach to identify compatible amino acid replacements for each cysteine is outlined in Figure 1C . We carried out alignments to query the chaperonin sequence database for the most closely related sequence with a substitution at each cysteine position.
These analyses informed the choice of residues to substitute to create a cysteine-less functional variant. One challenge in the implementation of this strategy was presented by sets of cysteines in steric contact, which in Mm Cpn are present in the equatorial and apical domains. Each of these sets consisted of a cluster of several cysteines in steric contact in the MmCpn structure.
We were concerned that mutation of one of these residues would require compensatory mutations in the other(s) that maintained the structural integrity of their contact. Accordingly, when the database was queried for the equatorial cysteines ( Figure 1B , D Magenta), we restricted hits to sequences with substitutions at all three positions. Likewise, for the two cysteines in the apical domain (Figure 1 B, D orange), we restricted hits to chaperonin sequences with both residues substituted.
Searching our database for non-cysteine variants of the equatorial cysteine positions C140, 470 & 484 returned a sequence from Methanococcus thermolithotrophicus with overall 85.8% identity to MmCpn but with non-cysteine residues at all three cysteine positions ( Fig 1D, Magenta). Notably, this was the most closely related sequence in the database with noncysteine variants at any of the three equatorial cysteine residues, suggesting that a mutation at any one of these positions necessitates a compensatory mutation at the other sites. The identities of the corresponding mutations in MmCpn are C140M, C470Y and C484T ( Figure 1D ).
Similarly, searching for coincident non-cysteine variants of the two apical Mm-Cpn cysteines yielded a sequence containing the substitutions C237E and C286V from Thermococcus sp. 4557 which is 66.3% identical to MmCpn ( Figure 1D ).
The remaining two cysteines are in the intermediate domain. Cys-359 was found to be mutated to valine in Haloarcula hispanica which is 59.2% identical to MmCpn. This was the most closely related organism with any substitution at that location. Finally, Cys-393 exhibited several amino acid substitutions in closely related sequences ( Figure S1 ). As such, we chose to incorporate serine at this position because it is both present in extant sequences and is isosteric with cysteine. Notably, MmCpn∆Cys incorporates an alanine at this position, which is also well represented in the database of homologs. All the above substitutions were introduced into MmCpn to generate a new cysteine-less variant herein termed Cys0 (MmCpn-Cys0).
The cysteine-less MmCpn-Cys0 is well expressed and supports ATP-driven cycling
While the previously derived MmCpn∆Cys could assembled correctly, it did not express well in Escherichia coli.This is illustrated by experiments where wild type (WT) and ∆Cys MmCpn were expressed from pET21a plasmids in E. coli BL-21. Following induction with IPTG, expression was monitored by SDS-PAGE of total lysates (Figure 2A ). WT MmCpn was highly expressed in soluble form and clearly visualized by Sypro Ruby staining, while the previously described Cpn∆Cys mutant protein was barely perceptible in the lysate. Importantly, the same experiment demonstrated that the rationally designed MmCpn-Cys0 variant was produced at much higher expression levels, comparable to WT (Figure 2A) . In a further test of assembly competence, we examined whether the Cpn variants remained soluble after treatment of the lysate with 55% ammonium sulfate (AS), as observed for the WT MmCpn ( Figure 2B ). Indeed, both WT and Cys-0 variants, but not the ∆Cys variant, were very soluble in 55% ammonium sulfate ( Figure   2B ). Accordingly Cpn Cys-0 could be purified with the MmCpn purification protocol established for WT. Figure 2C ). This observation is consistent with a decreased rate of chamber closure or an increase in the rate of chamber re-opening. To evaluate the likelihood of each explanation, we measured the ATP hydrolysis rate of MmCpn Cys-0 compared to WT. For all three ATP concentrations tested, the Cys-0 variant hydrolyzed ATP at comparable, albeit slightly lower rates that WT Cpn ( Figure 2D ). This result strongly suggests that the decreased level of proteinase protection seen in cycling Cys-0 is due to a decreased rate of closure and not faster re-opening which would manifest and increased ATPase rate.
Of note, both WT and Cys-0 chaperonins exhibit the previously described inhibition of ATP hydrolysis rates at high ATP concentrations (compare 200 and 1000 micromolar ATP in Figure   2D ). This indicated that MmCpnCys-0 preserves the allosteric regulation of ATP hydrolysis characteristic of group II chaperonins. Figure 3C ).
Finally, we compared the ATP-dependent production of folded Rhodanase when bound by MmCpn Cys-0 versus MmCpn WT ( Figure 3D ). Rhodanese folding results in active enzyme that can be measured using a colorimetric assay. The rhodanese-Cpn complex was incubated in the absence or presence of ATP or ATP-AlFx, and the extent of rhodanese folding was measured using an endpoint assay. Importantly, the cysteine-less MmCpn-Cys-0 promoted rhodanese folding as effectively as WT Cpn both under cycling conditions,i.e. in the presence of ATP, or when the complex is locked in the closed state with ATP-AlFx. Together, these experiments indicate that our approach enabled the design of a well folded, assembled and active cysteine-less chaperonin complex.
Discussion
We here describe a rational bioinformatic approach to engineer active cysteine-less variants of proteins using an analysis of extant sequences. Our premise is to exploit natural variation to identify amino acid substitutions compatible with a protein's structure and activity. Unless cysteines are essential for protein catalysis or to generate a specific structural or functional motif, such as a Zn-finger, it is likely that examination of orthologues of a protein of interest will identify suitable cysteine replacements compatible with its structure and activity. We documented the success of our strategy by engineering a cysteine-less variant of the group II chaperonin MmCpn. To our great surprise, this technique allowed us to define seven simultaneous point mutants that together could replace the cysteines in the protein while retaining a functional, well expressed complex. The unintuitive nature of the point mutations selected by this approach is worth emphasizing.
The common practice to eliminate cysteines by mutation to alanine or the isosteric amino acid serine often fails to yield active or stable protein variants. This is illustrated by analysis of the previously obtained cysteine-less Cpn mutant ∆Cys, which is less stable and less well expressed, indicating this approach is not the best choice for the chaperonin system. Furthermore, to enumerate and experimentally explore all possible, 20^7 (1.28 trillion), amino acid combinations is too onerous to be feasible. A remarkable feature of our approach is its ability to identify spatially or structurally linked replacements. For instance, this allowed us to replace cysteine clusters that are in steric contact in the folded protein. By identifying sets of non-cysteine residues that maintained the interaction in orthologous proteins, our approach permitted the replacement of the entire cysteine cluster without loss of protein integrity or activity.
To make this engineering approach available to other investigators we developed a software tool which we named Replacement at Endogenous Positions from eXtant sequences (REP-X).
The current (alpha) version of the software is available at (http://github.com/kmdalton/rep-x).
The basic design of the application is summarized in Figure 4 . We predict this software will enable other protein scientists to rapidly and rationally design cysteine-less protein variants, opening the way to introducing cysteines at specific positions for site specific labeling.
An important consideration for our approach, is that there is no intrinsic limitation on the amino acid type being replaced. REP-X can equally aid in the design of single tryptophan mutants for intrinsic fluorescence studies, be used to generate single lysine variants for site specific labeling by N-hydroxysuccinimide conjugates or to generate specific single amino acid variants for position specific labelling with stable isotopes for NMR experiments. Our results suggest that this technique can be particularly powerful in systems for which structural data are available in order to identify cysteines which are in close proximity.
Materials & Methods
MmCpn Expression Constructs
MmCpn WT and MmCpn∆Cys plasmids derive from previous work. Briefly, the sequence of the chaperonin was cloned into the Nde1 and BamHI of pET21a+ (EMD Chemicals) yielding 
Expression tests of chaperonin mutants
E. coli BL-21 pRosettas containing the three expression vectors were cultured in terrific broth with 100 ug/ml ampicillin and 30 ug/ml chloramphenicol overnight then diluted 1:1000 into 50 ml of fresh media. These cultures were grown at 37 C with 250 rpm shaking until reaching an OD600 between 0.9 and 1.0. The cultures were induced with 1mM IPTG and transferred to a 16 C incubator overnight. The following morning the cells were pelleted by centrifugation at 5,000 x g for 10 minutes and flash frozen in liquid nitrogen.
Frozen cell pellets were resuspended in 10 ml of MQA buffer and lysed in an Emulsiflex-B15 (Avestin). Lysates were cleared by centrifugation at 22,000 x g for 30 minutes. Ammonium sulfate was added to the cleared lysate to a final concentration of 55% saturation. After a 15 minute incubation at 4 C, the insoluble fraction was removed by centrifugation at 22,000 x g for 30 minutes. 2 ul of the lysed, cleared, and ammonium sulfate soluble fractions were loaded onto 15% Tris-glycine SDS Polyacrylamide gels and electrophoresed at 25 mA for 1 hour. Gels were stained with Sypro Ruby (ThermoFisher) and imaged on Typhoon scanner (GE).
Chaperonin purification
Expression, lysis, and ammonium sulfate cuts were performed as described in the previous section excepting that the culture volumes were increased to 1 L. Anion exchange and heparin affinity chromatography were performed as described previously 21 . After heparin chromatography, MmCpn solutions were concentrated in 15 ml centrifugal concentrators with a 100 kDa nominal molecular weight cutoff, buffer exchanged at least 3 times into MQA, concentrated to between 80 and 150 mg/ml, flash frozen in liquid nitrogen and stored at -80 C.
ATPase assay
A previously described enzyme coupled assay 22 
Proteinase K assays
Assays were performed as described previously 21 except that the chaperonin nucleotide reaction incubation time was extended to 60 minutes at 37 C. Briefly, ATPase buffer containing 0.25 uM MmCpn was pipetted onto the appropriate ATP conditions (no ATP, 1 mM ATP, 1 mM ATP + 1 mM AlNO3 + 6 mM NaF), and incubated at 37 C for 1 hour. Subsequently, 400 ng of proteinase K was added and the chaperonin was digested at room temperature for 10 minutes. Cy-3 rhodanese protection was performed just as the standard proteinase K protection assay except that 0.25 uM chaperonin was first added to 1 uM final concentrated rhodanese dissolved in 6mM guanidium buffered with 100 mM HEPES pH 7.4 for 10 minutes on ice and subsequently centrifuged for 10 minutes at top speed in a microcentrifuge. This sample was applied to the nucleotide conditions, proteinase, and quenched with PMSF as described above.
Rhodanese folding assay
Rhodanese folding was performed as described previously 20 . Briefly, 100uM denatured rhodanese in 100 mM HEPES pH 7.4 with 6M guanidinium chloride and 5 mM DTT was diluted 1:100 into ATPase buffer containing 0.25 uM MmCpn. Samples were incubated on ice for 10 minutes followed by a 10 minute spin at top speed in a 4C refrigerated microcentrifuge to pellet aggregated rhodanese. The samples were pipetted onto nucleotide conditions containing no ATP, 5 mM ATP, or 5 mM ATP + 1mM AlNO3 + 6 mM NaF and incubated for 60 minutes at 37 C. Rhodanese activity was then assayed colorimetrically as described previously 23 
Non-denaturing agarose gel electrophoresis
Samples were prepared as in the proteinase protection assays, but rather than being digested, they were loaded onto a 1% agarose gel with 1 mM MgCl222 and 80 mM MOPS pH 7.4, and electrophoresed for 1 hour at 100 volts and optionally stained with Sypro Ruby (Thermo Fisher) before imaging staining on a Typhoon Scanner (GE). Resulting fractions were dehydrated in a speedvac and resuspended to a final concentration of
Rhodanese Purification
Cy3-Rhodanese Labeling
After Mono-S chromatography, 400 ul of rhodanese solution was reserved from the purification. This solution was added onto a solution of Cy3-Maleimide dissolved in 20 ul of DMSO and incubated at room temperature for 2.5 hours. The labeling reaction was quenched with 10 ul of 1M DTT. This solution was then purified by size exclusion and denatured at described above. 
Figure Legends
